Pleurothotonus

Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics

Retrieved on: 
Tuesday, May 8, 2018
Neurological disorders, RTT, Neurology, Medicine, Psychiatry, Syndromes, Tardive dyskinesia, Antipsychotic, Dyskinesia, Psychosis, Typical antipsychotic, Pleurothotonus

Results from the RE-KINECT study showed that nearly 28 percent of patients treated with an antipsychotic had clinician-confirmed possible TD.

Key Points: 
  • Results from the RE-KINECT study showed that nearly 28 percent of patients treated with an antipsychotic had clinician-confirmed possible TD.
  • Over half of patients with clinician-confirmed possible TD were affected by uncontrollable movements in two or more body regions.
  • "It is important that psychiatrists and neurologists take these findings into consideration when managing patients treated with antipsychotic medications.
  • Now that we have approved treatment options for tardive dyskinesia, it is important to proactively screen patients for the symptoms of tardive dyskinesia and diagnose patients living with this condition."